Edwards Lifesciences' PASCAL System Outperforms Medical Therapy in Tricuspid Repair Trial

By Public Technologies
  • Edwards Lifesciences’ PASCAL tricuspid repair system outperformed medical therapy alone on the CLASP II TR trial’s six-month primary endpoint.
  • Reductions in tricuspid regurgitation and improvements in patient health status persisted through one year, with low adverse event rates at 30 days.
  • Results were presented at the Transcatheter Cardiovascular Therapeutics symposium.
  • The system received FDA approval for tricuspid valve repair in October 2026, following CE Mark certification in 2020.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021325BIZWIRE_USPR_____20261102_BW800980) on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk